Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; calcium hydrogen phosphate; lactose monohydrate; hyprolose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; lactose monohydrate; croscarmellose sodium; calcium hydrogen phosphate; hyprolose; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; calcium hydrogen phosphate; magnesium stearate; colloidal anhydrous silica; hyprolose; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 70 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; lactose monohydrate; hyprolose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 20 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; lactose monohydrate; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate; hyprolose; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 20 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; hyprolose; colloidal anhydrous silica; croscarmellose sodium; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 70 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - nilotinib hydrochloride monohydrate; nilotinib -

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - nilotinib hydrochloride monohydrate 165.45mg equivalent to 150 mg nilotinib anhydrous free base;  ;   - capsule - 150 mg - active: nilotinib hydrochloride monohydrate 165.45mg equivalent to 150 mg nilotinib anhydrous free base     excipient: colloidal silicon dioxide crospovidone gelatin iron oxide red iron oxide yellow lactose monohydrate magnesium stearate opacode ink black s-1-277002 poloxamer 188 titanium dioxide - tasigna is indicated for the: · treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase, · treatment of chronic phase and accelerated phase philadelphia chromosome positive chronic myelogenous leukaemia (cml) in adult patients resistant to or intolerant to at least one prior therapy including imatinib.